CYMABAY THERAPEUTICS INC stock forecast: up to 8.61 USD CBAY stock price prognosis
Forecast for Thu 30 Mar 2023 price
CYMABAY THERAPEUTICS INC stock price forecast for further price development up to 6.78% (time horizon: 1 day) and price target of 8.61 USD. Short-term (time horizon: 2 weeks) CYMABAY THERAPEUTICS INC share price prediction for 2023-03-30 with daily closed price projections
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
We also have one preclinical stage product candidate, CB-001 (a GPR120 agonist). Following is a review of PBC and NASH and our development progress in each indication. The primary outcome measure will be the composite biochemical responder rate at 52 weeks. In addition, over two dozen other compounds are currently in Phase 2 development in NASH. Finally, corresponding changes in GGT were -0.6%, -29.0%, -46.1% and -35.0%. 8226; Financial reporting and compliance. CB-0406 is a derivative of halofenate. We control only certain aspects of our CSPs' activities. As a result, increasingly high barriers are being erected to the entry of new products. Coverage policies and third-party reimbursement rates may change at any time. Charles A. McWherter, Ph.D. has served as our Chief Scientific Officer since 2013. We have incurred significant net losses since our inception. We do not maintain "key person" insurance for any of our executives or other employees. We may be the target of this type of litigation in the future.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 34.72/100
Good financial position.
Historical view, profit is growing.
Company revenue is not growing faster compared with the
Institutional ownership list is based on filling form information
Bollinger Bollinger Bands for CYMABAY THERAPEUTICS INC can provide the information where the market is moving based on price information.
CYMABAY THERAPEUTICS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for CYMABAY THERAPEUTICS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for CYMABAY THERAPEUTICS INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for CYMABAY THERAPEUTICS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for CYMABAY THERAPEUTICS INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for CYMABAY THERAPEUTICS INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for CYMABAY THERAPEUTICS INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for CYMABAY THERAPEUTICS INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio